A CHECKLIST FOR SUITABILITY OF BIOMARKERS AS SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER

被引：0
|
作者：
BOGOCH, S
BOGOCH, ES
机构：
[1] BOSTON UNIV, SCH MED, BOSTON, MA 02215 USA
[2] ONCOLAB, BOSTON, MA 02215 USA
来源：
JOURNAL OF CELLULAR BIOCHEMISTRY | 1994年
关键词：
ANTIMALIGNIN; CANCER ANTIBODY; CANCER ANTIGEN; CANCER VACCINE; CYTOTOXICITY; GLYCOPROTEINS; IMMUNOSURVEILLANCE; MALIGNIN;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
By reference to a ''checklist'' of requirements for substances or processes to qualify as surrogate endpoint biomarkers, both malignin and antimalignin antibody are found to be suitable for use in breast cancer chemoprevention trials. Antimalignin has been shown to be highly specific and sensitive, modulatable and reversible, detectable early in appearance of malignancy and upon recovery therefrom, and differentially expressed in high-risk individuals as compared with the general population. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码：173 / 185
页数：13
相关论文
共 50 条
  • [1] SURROGATE END-POINTS IN CHEMOPREVENTION OF BREAST-CANCER - GUIDELINES FOR EVALUATION OF NEW BIOMARKERS
    HILSENBECK, SG
    CLARK, GM
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 205 - 211
  • [2] CHEMOPREVENTION OF BREAST-CANCER - SURROGATE END-POINTS AND AGENTS IN SHORT-TERM CLINICAL-TRIALS - FOREWORD
    不详
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 1 - 1
  • [3] BIOMARKERS AS INTERMEDIATE END-POINTS IN CHEMOPREVENTION TRIALS
    LIPPMAN, SM
    LEE, JS
    LOTAN, R
    HITTELMAN, W
    WARGOVICH, MJ
    HONG, WK
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07): : 555 - 560
  • [4] Research priorities in biomarkers and surrogate end-points
    Aronson, Jeffrey K.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (06) : 900 - 907
  • [5] DETERMINATION OF BIOMARKERS FOR INTERMEDIATE END-POINTS IN CHEMOPREVENTION TRIALS
    LEE, JS
    LIPPMAN, SM
    HONG, WK
    RO, JY
    KIM, SY
    LOTAN, R
    HITTELMAN, WN
    CANCER RESEARCH, 1992, 52 (09) : S2707 - S2710
  • [6] SURROGATE END-POINTS
    ELLENBERG, SS
    BRITISH JOURNAL OF CANCER, 1993, 68 (03) : 457 - 459
  • [7] SURROGATE END-POINTS
    BOUVENOT, G
    REVUE DU RHUMATISME, 1994, 61 (11): : 711 - 713
  • [8] BREAST-CANCER CHEMOPREVENTION - STUDIES WITH 4-HPR ALONE AND IN COMBINATION WITH TAMOXIFEN USING CIRCULATING GROWTH-FACTORS AS POTENTIAL SURROGATE END-POINTS
    DECENSI, A
    FORMELLI, F
    TORRISI, R
    COSTA, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 226 - 233
  • [9] SURROGATE END-POINTS - ARE THEY MEANINGFUL
    FISHER, DM
    ANESTHESIOLOGY, 1994, 81 (04) : 795 - 796
  • [10] CLINICAL SURROGATE END-POINTS
    Palmeri, Sergio
    EJC SUPPLEMENTS, 2007, 5 (09): : 44 - 45
12345